Good Practices - Pharma Access

01/10/202606/10/2026

Data Integrity by Design in Pharma: ALCOA+ Across Automation and GxP Systems

In a pharma facility, someone will eventually look at every batch record, every sensor reading, and every operator signature and decide whether or not to trust it. That trust has a name in industry: data integrity. It’s the foundation of ALCOA+ pharma programmes, and it should not be added only after a system is already up and running. It has to be built in from the start, through every automated process and GxP-relevant system that touches your product.

This post walks through what ALCOA+ really means, how it relates to the regulations that support it, and what “designing for data integrity” looks like day-to-day across the automation and GxP systems that run a modern pharma facility.

What Is ALCOA+, and Why Does It Matter So Much?

ALCOA is an acronym used across pharmaceutical data integrity guidance. It stood for Attributable, Legible, Contemporaneous, Original, and Accurate. As the industry developed, four additional attributes became widely recognised: Complete, Consistent, Enduring, and Available, giving us ALCOA+.

These underlying data-integrity principles are reflected across regulatory expectations and guidance from authorities including FDA, MHRA, WHO, PIC/S and within EU GMP requirements. ALCOA+ means that each data point on the ground at your facility must answer a simple set of questions: Who made the data? Is it readable? Was it captured at the time the activity was performed? Is it the original, unaltered capture? Is it accurate, complete, and available when needed throughout its required retention period?

In pharmaceuticals, the breakdown of data integrity is typically caused by a breach of one of the principles. A lost timestamp can undermine evidence that data was recorded contemporaneously. The Original and Complete attributes can be compromised by an overwritten value with no trace of the previously recorded information. This is not some theoretical fear. FDA guidance itself notes an increase in data integrity lapses identified during CGMP inspections. U.S. FDA

The Regulatory Backbone: 21 CFR Part 11, EU GMP Annex 11 and GAMP 5

ALCOA+ describes the attributes expected of trustworthy data. Regulations and industry guidance help translate those attributes into controls for the computerised systems that create, process and maintain it.

21 CFR Part 11 Requirements for Electronic GxP Records

21 CFR Part 11 pharma regulations detail the technical and procedural controls that applicable electronic records and electronic signatures must meet within its FDA-regulated scope. This includes audit trails that record the date and time of operator entries and actions that create, modify, or delete electronic records, protection of records throughout their retention period, and electronic signatures that are linked to one person and cannot be transferred to another. A system that meets Part 11 does not necessarily mean that all ALCOA+ expectations are automatically satisfied, and where electronic records fall within FDA-regulated predicate-rule requirements, Part 11 should be considered alongside the applicable GxP requirements.

EU GMP Annex 11 and Computerised Systems

For pharmaceutical operations subject to EU GMP, Annex 11 provides requirements for computerised systems used as part of GMP-regulated activities. It requires a risk-based approach across the system lifecycle, with appropriate validation, security, data management and controls based on the system’s impact on patient safety, data integrity and product quality.

GAMP 5 and Risk-Based Computerised System Validation

ISPE GAMP 5 takes a different approach. It does not simply prescribe a fixed list of record-keeping controls, but rather offers a framework for validating the computerised systems that create and maintain those records. GAMP 5 uses software categorisation as one input within a broader risk-based lifecycle approach, so a simple stand-alone instrument may require a different level of validation and assurance than a fully integrated manufacturing execution system, depending on intended use, GxP impact, complexity, novelty and risk. The goal is to apply proportionality to the validation effort based on the actual risk the system poses to patient safety and product quality, rather than applying the same level of assurance effort to every system.

Audit Trail Pharmaceutical Systems: The Evidence Behind Every Record

If ALCOA+ is the standard and Part 11 and GAMP 5 are part of the regulatory and good-practice framework, the audit trail is where the evidence actually resides. An audit trail pharmaceutical system generates a secure, computer-generated, time-stamped record of relevant operator entries and actions that create, modify, or delete electronic records within the system.\

A good audit trail is more than an activity log. Every change is attributed to a specific user, the original value is retained along with any edit, and where an audit trail is required, it should be protected so normal users cannot amend or disable it. During an inspection, audit trails can be reviewed to assess whether GxP-relevant data has been created, changed, or deleted with appropriate traceability. Audit-trail functionality alone is not sufficient; relevant audit trails should also be reviewed at a frequency and depth defined through risk assessment.

How Automation Helps Pharma Manufacturers Build Data Integrity In

And this is where automation makes sense. To understand how automation supports pharma manufacturers in fulfilling those expectations, we need to understand what manual, paper-based processes can get wrong when they are not appropriately controlled. Manual and paper-based records can depend on timely and accurate human entry, while poorly controlled processes increase the risk of delayed recording, transcription errors, or incomplete traceability.

Several of these risks can be reduced by automated systems by design:

Data collection at the point of activity rather than having someone transcribe a reading later, which goes a long way to supporting the contemporaneous and original principles.
Implementing role-based access to allow only authorised personnel to create or modify certain records.
Automatically generating secure audit trails where configured and required, so relevant changes are recorded with appropriate traceability.
Standardising data formats and units, reducing transcription errors when values are manually moved between systems.
It flags out-of-range results in real time, catching problems during production rather than days later in batch review.

Just because a system is digital doesn’t mean data integrity happens automatically. A digital system not properly validated and configured does not resolve the data integrity problem. It can simply move the risk to a different medium where certain integrity issues may be less visible. European Commission

MES and QMS in Pharma: Where Data Integrity Lives Day to Day

On a production floor, MES and QMS can carry a significant part of the day-to-day data integrity workload. In pharma facilities, MES and QMS can be integrated to connect the line activity to the quality decisions that are made about it.

A Manufacturing Execution System (MES) digitises work instructions, supports manufacturing workflows and electronic batch records, and can capture process data from shop-floor automation, decreasing the human error inherent in paper-based batch records. Quality Management Systems (QMS) and electronic QMS platforms support the broader quality processes that surround manufacturing itself, including things like deviations, corrective actions, and document control.

When MES and QMS are properly integrated, a quality event on the production floor can be transferred directly into the quality system, reducing the need for someone to re-enter data and the workload and transcription errors involved with the two systems.

Below and alongside the MES layer, PLC, DCS, SCADA and plant historian systems can also generate, process and retain GxP-relevant manufacturing data. Their architecture, access controls, time synchronisation, interfaces and data-retention strategy therefore form an important part of data-integrity-by-design.

BMS EMS Pharma: Data Integrity Beyond the Production Floor

Data integrity isn’t limited to manufacturing records. Building Management Systems (BMS) and Environmental Monitoring Systems (EMS) for pharma generate their own continuous stream of facility and environmental data, some of which may be GxP-relevant and therefore requires appropriate data-integrity controls.

A BMS is a control and data recording facility for conditions such as HVAC performance, pressure differentials, and utility status. An EMS can monitor, collect and trend environmental parameters such as airborne particle counts, temperature, relative humidity and other defined conditions, while viable microbiological monitoring data may also be incorporated according to the facility’s environmental monitoring strategy and applicable GMP requirements. GxP-relevant records generated by both systems should be managed in accordance with applicable ALCOA+ and data-integrity expectations because demonstrating that required cleanroom conditions were maintained depends on trustworthy monitoring data. MHRA

Designing for Data Integrity, Not Inspecting for It

The underlying message is that data integrity is best when built into a facility’s systems from the outset, not added in response to a warning letter. Adding audit trails, role-based access, or proper validation documentation to a system once it is live is far more disruptive and costly than building those controls into the system during the design and commissioning phases.

Common Data Integrity Failures and How Design Prevents Them

Across facilities, several common problems appear when systems and processes have not been designed with data integrity in mind from the start:

Shared login credentials: Breaks attributability, because no one can prove who made an entry.
Manual transcription from: one system to another increases the risk of errors and can compromise traceability to the original data if appropriate verification controls are not in place.
Audit trails that are turned off or incomplete, often because the system was set up for convenience rather than compliance.
Inconsistent time sync between systems – makes it hard to prove that records were actually contemporaneous.
Insufficient planning of backup and recovery, risking the Enduring and Available attributes under ALCOA+.
All of these can reflect weaknesses in design, configuration, procedures and data governance, not an inevitable consequence of using electronic systems.

Why This Matters at the Facility Design Stage

To get this right, automation, MES, QMS, BMS, and EMS design need to be considered alongside facility layout and HVAC planning, not an afterthought once construction and installation is complete. The engineering teams at Pharma Access manage the automation and building system design (BMS, EMS, and process automation) as part of the same coordinated project that encompasses HVAC, cleanrooms, and utilities. Building data integrity controls from the start can reduce the need for costly retrofits when gaps are identified after a facility has entered operation. Learn more about our approach on the Pharma Access about.

Wrapping Up

Data integrity ALCOA+ Pharma work is not a checklist to be completed before an inspection. It’s a design principle that should inform the way every automated system, from a simple sensor to a complete manufacturing execution system, captures, stores, and protects data from the moment it is generated. Facilities that bake these expectations into their automation and GxP systems from day one spend far less time explaining gaps to an inspector later and far more time trusting the data their own systems produce.

FAQs

What does ALCOA+ stand for?

ALCOA is an acronym for Attributable, Legible, Contemporaneous, Original, and Accurate. The “+” adds Complete, Consistent, Enduring, and Available to provide nine principles that define reliable data in a GxP environment.

How does 21 CFR Part 11 relate to ALCOA+?

21 CFR Part 11 describes the technical and procedural controls, including audit trails and electronic signatures, for electronic records and electronic signatures that fall within its scope. Those controls support data integrity and the broader ALCOA+ principles but do not, by themselves, establish that every ALCOA+ expectation has been met.

What is the difference between MES and QMS in a pharma facility?

MES captures and manages data from production activities and manufacturing workflows in real time. A QMS is responsible for quality processes like deviations, corrective actions, and document control. When appropriately integrated, the two can reduce manual re-entry and the associated risk of transcription errors.

Why do BMS and EMS systems need to meet data integrity standards too?

These systems produce the environmental and facility data that demonstrates that a cleanroom or storage area was maintained under the conditions needed for GMP manufacturing. Where this data is GxP-relevant, its integrity and traceability need to be appropriately controlled because decisions about facility and product conditions may depend on it.

Can data integrity be added to a system after it is already running?

It can, but it is far more disruptive and costly than building in controls such as audit trails, role-based access, and validation documentation at the beginning of a facility project.

01/10/202606/10/2026

Schedule M Compliance in 2026: Engineering Gaps Indian Pharma Plants Still Need to Address

The revised Schedule M may have seemed like just a paperwork change for many Indian pharma manufacturers. Revise the SOPs. Train the quality team. Strengthen the documentation. Move on. That approach may address some of the requirements. It doesn’t address those sections that affect the actual building and engineering systems.

This post takes a look at the revised Schedule M requirements in India from an engineering perspective: what the rule expects from a facility’s layout, utilities, and cleanroom design, and where plants still fall short even after their paperwork is in order.

A Quick Recap of Where Things Stand

Schedule M forms part of the Drugs Rules, 1945, and sets out Good Manufacturing Practice requirements for pharmaceutical manufacturing in India. The revised version was notified through G.S.R. 922(E), dated 28 December 2023. The notification also updated references in the Drugs Rules from “Good Manufacturing Practices” to “Good Manufacturing Practices and Requirements of Premises, Plant, and Equipment for Pharmaceutical Products,” reinforcing the broader scope of the revised framework.

Large manufacturers with a turnover above INR 250 crore were required to comply from 29 June 2024. Manufacturers with turnover up to INR 250 crore were subsequently granted a conditional extension until 31 December 2025, subject to the requirements of G.S.R. 127(E). From 1 January 2026, revised Schedule M became effective for manufacturers in this category.

The revised rule is more closely aligned with contemporary WHO GMP requirements and broader international GMP expectations. It specifically includes structured Pharmaceutical Quality Systems (PQS), Product Quality Review (PQR), Quality Risk Management (QRM), and strengthened requirements for documentation, traceability and validated computerised systems. None of this is optional anymore, and none of this can be solved by documentation alone. Ministry of Health & Family Welfare

Why Engineering Gaps Are the Harder Problem

Training and templates can address documentation gaps. Construction requires time, money, and planning that many plants may not have budgeted for when the revised rule first came out. Construction and system modifications are what close physical engineering gaps.

Here’s the difference that counts. A written SOP for cleaning validation can be rewritten in a week. You can’t write a document that turns a cleanroom with inadequate airflow control, pressure relationships, or contamination-control design into a compliant environment. The building and engineering systems have to be altered.

This is the real risk of 2026 compliance, particularly for sites built ten or fifteen years ago under the older, less prescriptive version of Schedule M.

Where Pharmaceutical Plant Layout Design Falls Short

One of the areas revised Schedule M addresses directly is pharmaceutical plant layout, and that’s where older facilities tend to have the most trouble.

Material and Personnel Flow

The new rule calls for a facility layout that keeps people and materials moving throughout the building in a controlled, logical manner, with interactions managed in ways that minimise contamination and mix-up risks. Many older Indian plants were developed under different design expectations, with corridors and access points constrained by available space. Retrofitting a clean flow pattern into a building not designed for it often involves moving walls, relocating airlocks, or, in some cases, redesigning an entire wing.

Cleanroom Classification and Zoning

Cleanroom classification establishes the required level of airborne particulate cleanliness, while the associated GMP grade and process requirements influence air change rates, filtration, airflow, environmental control and gowning requirements for each zone in the plant. If a facility was built to an older classification strategy, the production and support areas may need to be reassessed and its air handling systems redesigned to match current process and classification requirements. That’s not a minor tweak. It may include changes to ductwork, filter housings, air distribution, monitoring systems and pressure relationships throughout the building.

Pharmaceutical Water and Critical Utilities

The amended standard sets out design, qualification and monitoring expectations for pharmaceutical water and other utilities that can affect product quality, including steam, gases, compressed air and HVAC where applicable. Existing utility distribution arrangements in older plants may not adequately address current contamination, capacity, monitoring or process requirements. One of the more difficult engineering challenges a brownfield project can face is modifying these systems without unnecessarily disrupting production.

The HVAC Problem Nobody Budgeted For

HVAC systems are a frequent topic of discussion regarding the revised Schedule M gaps and not without good reason. Legacy systems may not support the filtration, pressure relationships, airflow patterns, temperature/humidity control or contamination-control strategy required for the intended process and GMP grade. A plant may look acceptable during a visual inspection while performance data reveal gaps in environmental control.

Remediation may involve air balancing, control-system upgrades, additional monitoring, changes to filtration or ductwork, or replacement or augmentation of air handling units, depending on the gap identified. All of this has to be installed on a building that is often still running production. That combination of technical challenge and operational continuity is precisely why so many plants are behind schedule on this compliance item.

Brownfield Pharma Upgrades: A Different Kind of Project

Upgrades to brownfield pharma sites are not just smaller, simpler versions of a new build. They face their own constraints that a greenfield project never has to deal with.

A brownfield project must deal with the fixed column grids, existing ceiling heights, and utility entry points that were there for a totally different process. In many cases, the facility also has to keep producing while construction is going on, so maintaining controlled separation during construction is an engineering challenge in itself, not just a compliance consideration.

There are a few things that distinguish a well-planned brownfield upgrade from a poorly executed one:

Complete facility audit before any design work begins. This means the building structure, current utility capacity, cleanroom classifications, and validation status must be checked before committing to a design.
Building in phases. By breaking the work into sections, only part of the plant is taken offline at a time, rather than the whole facility.
Physical separation of building and production spaces. Temporary barriers and designated construction access routes keep dust and foot traffic out of live manufacturing areas.
Utility hookups coordinated with scheduled shutdowns. Connections to shared power, water, or HVAC systems are made during approved shutdown windows, rather than being improvised during execution.
Documentation updated regularly during construction. Change control records and validation documents are updated as the work progresses, not stitched together after the fact.
Requalification before any area is returned to GMP use. When a section is complete, it goes through the applicable commissioning, qualification or requalification, validation and QA release activities before production can resume there.

Skipping any of these steps can make compliance gaps harder to close after the fact than they would have been if addressed during planning. Government of India / Press Information Bureau

What This Means for Plant Owners Right Now

If your facility has not yet done a formal gap assessment against the revised rule’s engineering requirements, now is the time to do it, rather than waiting for deficiencies to emerge during regulatory assessment.

The gap assessment should include:

Current cleanroom classification vs. cleanroom classification your product lines actually need, where applicable
HVAC performance data (pressure differentials, air change rates
Utility design, capacity, distribution and segregation requirements for water, steam, and compressed air systems
Material and personnel flow mapped to your current layout

Current validation and qualification status for all major systems

For manufacturers weighing whether to retrofit an existing facility or build a new one, that decision often boils down to timeline, budget, available utility capacity, and whether the existing site can technically support what the revised rule now expects. An engineering team experienced in both types of projects can clearly set out that comparison before construction decisions are locked in.

Pharma Access supports pharmaceutical manufacturers with this type of assessment, including facility layout, HVAC and cleanroom design, critical utilities and the CQV work required to upgrade an existing plant to current GMP requirements while managing production constraints. For plants that are at the outset of a complete renovation, Pharma Access also supports greenfield builds where the layout, utilities, and cleanroom zoning are designed to current requirements from the start.

A Few Final Thoughts

Revised Schedule M compliance is more than a documentation exercise. It speaks to the physical structure of a plant, from the way air flows through a cleanroom to how people and materials move throughout the building. Manufacturers that treat pharmaceutical plant layout design and HVAC upgrades as afterthoughts may face greater remediation pressure during inspection readiness. Getting ahead of the engineering requirements is particularly important for brownfield pharma upgrades, where early planning can make the difference between a manageable renovation and a rushed one.

Frequently Asked Questions

What is the deadline for revised Schedule M compliance in India?

Revised Schedule M became effective for manufacturers with turnover above INR 250 crore from 29 June 2024. Manufacturers with turnover up to INR 250 crore were granted a conditional extension until 31 December 2025, with the revised requirements effective for this category from 1 January 2026.

Does revised Schedule M require physical changes to a pharma plant, or just documentation?

Both. The rule requires structured quality systems and documentation, but it also has specific requirements for facility layout, cleanroom classification, HVAC design and qualification, and utility design that can require physical or system modifications where gaps are identified.

What is the difference between a brownfield and greenfield pharma project?

Greenfield projects are new facilities developed without the physical and operational constraints of an existing manufacturing site. A brownfield project is an upgrade or expansion of an existing, often operational, facility, which requires working around fixed infrastructure and maintaining production continuity during construction.

Why do older pharma plants struggle with HVAC compliance under the revised rule?

Older HVAC systems may struggle to achieve the filtration, pressure relationships, airflow control, temperature/humidity control or containment performance required for the intended process and GMP environment. Remediation may involve air balancing, controls and monitoring upgrades, filtration or ductwork changes, or replacement or augmentation of air handling units, which can be more complex in a facility that remains operational.

How does pharmaceutical plant layout design affect Schedule M compliance?

The layout design determines the flow of material and people through a facility, the zoning and required cleanliness or GMP grade of applicable areas, and the control of contamination risk. A layout that has not been designed with these flows in mind often requires a large amount of redesign work to meet the current requirements.

26/09/202606/10/2026

GCC GMP Requirements for Pharmaceutical Manufacturing Facilities: A Plain-Language Guide

If you are building or upgrading a pharmaceutical plant in Saudi Arabia, the UAE, Qatar, Oman, Bahrain, or Kuwait, you’ve probably come across the term ‘GMP’ more times than you can count. It is what you hear on every registration form, every inspection report, and every conversation with regulators. But what does this mean for a factory floor?

This guide gives a simple-to-understand overview of the GCC GMP requirements for pharmaceutical manufacturing. No dense legal jargon, just the information you need before you design, build, or operate a plant in the Gulf region.

What GMP Actually Means for a Pharma Plant

Good Manufacturing Practice (GMP) is the part of pharmaceutical quality assurance that ensures medicines are consistently produced and controlled to the quality standards appropriate to their intended use. The point is simple: every batch of medicine should be consistently manufactured and controlled – with risks such as contamination, cross-contamination, mix-ups, and processing errors appropriately managed.

For a factory, this means just about everything:

Building layout
Composition of walls and floors
How air flows in production rooms
How the equipment is cleaned and calibrated
How records are kept
How staff are trained

GMP is not simply a certification label applied to a building. It is a way of running the place, and regulators check it through documented evidence as well as actual manufacturing practices.

How the GCC Handles Drug Registration and GMP

The six Gulf countries (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain and Oman) have put in place a common system to harmonise parts of the drug registration process for manufacturers. The system is operated by the Gulf Health Council (GHC) in Riyadh and its Central Gulf Committee for Drug Registration.

The basic idea behind GCC central drug registration GMP rules is:

The manufacturer sends a centralised registration dossier through the Gulf Health Council system rather than repeating the complete assessment separately across each participating market.
GHC reviews the product for quality, safety, and effectiveness.
A technical team can visit the manufacturing site to verify that it adheres to Good Manufacturing Practices and applicable international manufacturing standards.
Once approved, the centralised pathway can reduce duplication in regulatory assessment across GCC member states.
The centralised route operates alongside applicable national regulatory pathways. Companies targeting individual markets must also consider requirements of national authorities such as Saudi Arabia’s SFDA or the UAE’s Emirates Drug Establishment (EDE).
Country-specific requirements relating to manufacturing-facility licensing, product registration, pricing, labelling, importation, local representation, or other regulatory activities may still apply depending on the market and regulatory pathway.

Core GMP Facility Requirements in the GCC

If it is a central system or a national system, the physical plant has to meet applicable GMP requirements established by the relevant regulatory authority. These are some of the core areas addressed during GMP assessment and inspection.

Building and Premises Design

The layout has to follow the logic of production, from raw material input to finished product output. Rooms should be arranged in such a way that materials and people move through controlled routes that minimize crossings and interactions that could create contamination, cross-contamination, or mix-up risks. Surfaces should be smooth, washable, and without crevices where dust or microbes can collect.

Cleanrooms and HVAC Systems

This is an area where first-time pharmaceutical facility projects can encounter significant challenges. Clean room validation for sterile products are classified according to defined airborne particle concentrations. Air handling systems must maintain airflow patterns and pressure relationships between rooms appropriate to the product, process, and contamination-control strategy. Temperature, humidity, and airflow should be monitored at a frequency appropriate to the process and qualified operating conditions, with alarms provided for critical parameters where excursions could affect product quality or contamination control.

Equipment and Utilities

Production machines need to be appropriately qualified before routine use and maintained in a qualified state, with requalification performed where required based on defined intervals, changes, periodic review, or quality risk assessment. Water systems, especially purified water and water for injection systems, also require their own qualification and periodic testing. Compressed air and other utilities that contact the product are also subject to GMP scrutiny.

Documentation and Quality Systems

Every GMP-relevant operation should have an approved written procedure, and each batch must have a record that the procedure was followed. Supporting quality documentation includes deviation reports, change controls, CAPA records, calibration records, training records, and qualification and validation documentation. Inspection activities typically include detailed review of these records, because documentation gaps can indicate weaknesses in the pharmaceutical quality system.

Personnel and Training

Training should be provided to staff in production areas to cover their role, and this training should be documented and refreshed on a regular basis. Gowning procedures for cleanroom entry, hygiene practices, and microbiology awareness where relevant to the operation all form part of the picture.

Saudi Arabia’s SFDA and Its GMP Framework

The Saudi Food and Drug Authority (SFDA) plays a central role in regulating pharmaceutical manufacturing and GMP compliance in Saudi Arabia. SFDA became the 56th PIC/S Participating Authority on 1 July 2023 following completion of the PIC/S accession assessment process. PIC/S supports international harmonisation of GMP inspection practices among participating authorities, strengthening alignment between participating inspectorates and internationally recognised GMP inspection principles.

This is important for manufacturers looking for a GCC pharmaceutical manufacturing footprint because SFDA’s regulatory framework requires evidence of GMP compliance and allows the authority to inspect manufacturing sites to verify implementation. A GMP certificate or previous inspection history does not automatically replace an SFDA inspection, so the applicable registration and inspection requirements should be confirmed for each manufacturing site.Saudi Food and Drug Authority

Steps to Get a Pharmaceutical Factory GCC-Ready

If you are starting from scratch or upgrading an old plant, here is a simple sequence to follow:

First, define your product scope: Tablets, sterile injectables, biologics, and APIs all have different process, environmental-control, containment, and utility requirements, so this decision dictates much of what happens downstream.
Design the facility to GMP flow: Get engineering involved early so the layout of the building, HVAC design, and flow of personnel and materials are consistent with GMP and contamination-control requirements from day one and not retrofitted later.
Qualify utilities and equipment: Water systems, HVAC, and process equipment must undergo appropriate lifecycle qualification activities covering installation, operation, and performance requirements, as applicable, before routine GMP use.
Build your quality system side by side: SOPs, batch records, training programmes, and other required quality documentation should be developed alongside facility delivery and be in place before routine GMP manufacturing begins.
Conduct a GMP readiness assessment or mock inspection: A structured review against applicable SFDA, national regulatory, or PIC/S-aligned expectations is a good way to identify gaps before a regulatory inspection.
File for registration: Decide whether the GCC centralised route or the applicable national registration pathway best fits your target markets and regulatory strategy. Gulf Health Council

Common Challenges Manufacturers Run Into

There are some recurring issues in GMP facility requirements for GCC projects:

Cleanroom classifications or environmental-control requirements are selected without sufficient consideration of the actual product and process risk. This can cause redesign, rework, or qualification challenges downstream.
Late-stage value engineering changes HVAC capacity, zoning, or control philosophy without adequately assessing the impact on qualified operating conditions.
Documentation systems are created as an afterthought instead of being developed alongside the physical build and qualification programme.
Teams assume there is one identical GCC standard for every market and overlook national regulatory nuances between Saudi Arabia, the UAE, and other member states.
Integrating engineering and GMP requirements from the beginning can reduce many of these avoidable project risks. This is the type of work that Pharma Access specialises in, because GMP-driven facility design must consider regulatory expectations from the first drawing, not after construction is complete.

Why Early Engineering Input Matters

Many avoidable GMP readiness issues can originate during the design stage. In the first few weeks of a project, decisions are made about cleanroom classification, HVAC zoning, and material flow, and those decisions are expensive to reverse once construction has progressed. This is precisely the step that Pharma Access works with pharmaceutical manufacturers on, developing facility designs, cleanroom layouts, HVAC and utility strategies, and validation approaches around the compliance requirements against which the plant will ultimately be qualified and inspected. Addressing these details before construction starts can reduce redesign, rework, and qualification challenges ahead of regulatory inspection.

And for companies deciding whether to build greenfield or upgrade an existing site, Pharma Access also provides support for commissioning, qualification and validation (CQV) work – where design requirements, system performance, and applicable GMP requirements are verified and documented against the completed facility and installed systems.

A Few Final Thoughts

The GMP requirements of the GCC for pharmaceutical manufacturing are not one fixed checklist. These are systems that combine a regional registration system through the GHC with national oversight by bodies such as Saudi Arabia’s SFDA and the UAE’s EDE, supported by internationally recognised GMP principles and the specific requirements adopted by each national authority. Get the facility design, documentation, and training right from the start, and you create a stronger foundation for qualification, regulatory inspection, facility licensing, and ongoing GMP compliance. World Health Organization

Frequently Asked Questions

What is the difference between GCC-DR and national drug registration?

GCC central registration is a harmonised pathway operated through the Gulf Health Council for the assessment and registration of pharmaceutical companies and products across participating GCC markets. National registration is handled through the relevant country authority, such as Saudi Arabia’s SFDA or the UAE’s EDE, and country-specific regulatory requirements may still apply.

Does every GCC country have the same GMP standard?

No. GCC cooperation provides harmonised elements of pharmaceutical registration and GMP oversight, but manufacturing-facility licensing, inspections, documentation requirements, and implementation remain subject to the applicable national regulatory authority. Requirements should therefore be assessed for each target market rather than assuming that one identical GMP framework applies throughout the GCC.

How long does GMP certification take for a new pharmaceutical facility in the GCC?

There is no single GCC-wide timeline. The duration depends on the relevant national authority, product and manufacturing scope, facility readiness, completion of qualification and validation activities, documentation status, inspection scheduling, and closure of any regulatory observations.

Can a foreign GMP certificate replace a physical inspection in Saudi Arabia?

Not automatically. A current GMP certificate and previous inspection history can form part of the manufacturer’s regulatory documentation, but SFDA retains authority to inspect manufacturing sites to verify GMP implementation. The applicable inspection requirements should therefore be confirmed for each site and regulatory pathway.

What causes the most GMP inspection failures in pharmaceutical factories?

Inspection observations can arise across the pharmaceutical quality system, premises, equipment, documentation, production, qualification and validation, utilities, personnel practices, and contamination-control systems. For example, SFDA’s published 2025 GMP inspection analysis identified quality management systems, premises, equipment, and documentation among the most frequently cited deficiency areas.

25/09/202606/10/2026

Cold Chain Warehouse Design for Biologics & Vaccines: A Practical Guide

A biologic or vaccine can be affected if it is kept outside its approved temperature range, and there is often no visible sign that a temperature excursion has affected product quality. This is the core problem that pharmaceutical cold chain warehouse design needs to address. It is not just a warehouse for boxes but part of the product quality and storage-control strategy itself.

This guide takes you through the real elements of designing a compliant cold storage facility from layout and HVAC pharma industry decisions to the temperature mapping work that proves the design holds up.

Why Cold Chain Warehouse Design Is Different

A typical warehouse is measured by the amount of volume it can move and store. But a pharmaceutical cold chain warehouse is measured by something narrower and less forgiving: whether products throughout the qualified storage volume remain within their specified storage conditions.

The most typical range for pharma cold storage design is 2°C to 8°C, which is widely used for many vaccines and temperature-sensitive pharmaceutical products. Some products need stricter controls. Some may require frozen storage, while others may require ultra-cold storage, depending on the approved product requirements. Each of these bands has its own equipment, insulation, and monitoring needs, and often a single warehouse needs to support more than one of them at a time.European Commission

The Regulatory Backbone: GDP

Good Distribution Practice (GDP) provides the regulatory framework that applies to the storage, handling and movement of pharmaceutical products through the supply chain. GDP warehouse design should provide for appropriate temperature monitoring, calibrated sensors traceable to a recognised standard, and alarm systems that can alert responsible personnel when excursions occur. EU GDP requires environmental monitoring equipment to be calibrated at defined intervals, with calibration traceable to national or international standards, and requires appropriate alarm systems for excursions from predefined storage conditions.

GDP typically expects a few things from a warehouse:

Qualified and monitored storage areas, not only cooled
Written procedures for what to do in case of a temperature excursion
Records retained in accordance with applicable regulatory and national retention requirements
Qualified storage zones that are clearly defined, with segregation applied where storage conditions, product status or risk require it

None of this is by accident. It has to be designed into the facility and then proven through testing before the building is occupied.

Main Elements of Pharmaceutical Cold Chain Warehouse Design

Zoning and Layout

Typically, a vaccine warehouse design calls for multiple temperature zones under one roof: ambient storage for products that do not require refrigeration, a 2-8°C pharmaceutical storage zone for many vaccines and temperature-sensitive pharmaceutical products, and sometimes a separate frozen or ultra-cold zone for specialty products. Each zone needs appropriate environmental control, defined monitoring points, and suitable physical separation so that the conditions in one zone do not adversely affect another.

Loading docks are a special consideration. Products can be particularly susceptible to temperature swings during receiving and shipping, so a well-designed facility may use airlock-style anterooms, dock shelters, rapid doors, temperature-controlled staging or other appropriate measures that restrict the amount of outside air reaching the cold zones when doors are opened.

HVAC and Refrigeration System Design

The chilled zone is one of the most critical parts of the building to get right. For standard 2-8°C storage, refrigeration capacity and air distribution need to maintain the specified range throughout the qualified storage volume without creating localised hot or cold spots. Supply-air temperature and airflow rates should therefore be determined from room loads, racking configuration, door-opening patterns, product sensitivity and qualification requirements rather than from a single fixed design value.

The airflow pattern is as important as the setpoint. The selected supply and return arrangement, combined with controlled airflow, should promote even temperature distribution throughout the storage area rather than creating pockets that are warmer or colder than the rest of the room.

This change is important because pharmaceutical guidance focuses on demonstrating temperature uniformity and identifying areas affected by cooling coils, cold-air streams, heat sources or air-distribution problems rather than prescribing one universal supply-air temperature or airflow arrangement.

Backup Power and Redundancy

A prolonged power outage or refrigeration failure can put temperature-sensitive pharmaceutical products at risk. Good facilities consider backup power, appropriate refrigeration redundancy and battery-backed monitoring systems based on the facility’s risk assessment, and the design should consider how long the building can maintain its temperature range in the event of total power loss.

Temperature Monitoring, Alarms and BMS/EMS Integration

Cold chain performance depends not only on refrigeration but also on how environmental conditions are monitored, recorded and escalated. Monitoring locations should be established using temperature-mapping and qualification results, with calibrated sensors positioned at representative or worst-case locations as appropriate.

Where BMS or EMS platforms are used, their monitoring functions, alarm handling, data retention, backup arrangements and qualification requirements should be clearly defined as part of the facility design and quality strategy.

WHO guidance recommends temperature monitoring devices in temperature-controlled rooms, cold rooms and freezer rooms, with sensors positioned where the greatest temperature variability is expected. It also recommends high- and low-temperature alarms and states that automated, continuous monitoring is preferable.

Temperature Mapping: Proving the Design Works

One part of the job is building a warehouse to specification. Pharmaceutical warehouse temperature mapping is the study that demonstrates the finished facility actually does maintain the specified temperature conditions throughout the qualified storage volume, not just at the thermostat.

A typical mapping study goes as follows:

Scope definition: From the main storage areas to the cold rooms, freezers, quarantine areas, receiving or loading bays, define the spaces in which temperature-sensitive products are stored or handled.
Install calibrated sensors throughout the space: The number and location of sensors are based on the risk involved and the size and layout of the warehouse, rather than a fixed grid. Sensor placement should be justified considering shelving, racking, room geometry and known airflow patterns.
Conduct the study under representative conditions: For warehouses and other ambient storage areas, WHO guidance typically recommends a minimum of seven consecutive days; for cold rooms and freezer rooms that are not critically affected by ambient temperature variations, the study may run for 24 to 72 hours, or longer if justified. Door-opening or power-failure challenges should be included where required by the approved qualification protocol and risk assessment.
Consider seasonal conditions: Where storage areas are affected by seasonal temperature variations, mapping may be needed during the warmest and coldest conditions. WHO guidance notes that two-season mapping is typically not necessary for cold rooms and freezer rooms.
Find hot spots and cold spots: Mapping results are used to identify suitable permanent monitoring locations, including areas that experience temperature extremes or represent worst-case conditions. EU GDP similarly states that monitoring equipment should be positioned according to mapping results in areas experiencing extremes of fluctuation.
Document everything: The final report should state whether the study met the acceptance criteria and identify the locations of hot and cold spots and any HVAC adjustments that are a result of the findings.
Re-mapping is not a one-off occurrence either: The frequency should be based on the monitoring strategy and risk assessment, with WHO giving every three years as one example of periodic mapping, and it should be repeated sooner if the warehouse layout changes, refrigeration or temperature-control systems are modified, storage patterns change materially, or monitoring data indicates unexplained variability.

Know More : World Health Organization

Common Design Mistakes to Avoid

In cold chain warehouse projects that end up in compliance trouble, these patterns show up again and again:

Making loading docks an afterthought. This is where excursions are more likely to occur because products may be exposed to changing external conditions, and it is difficult to rectify airlock, dock shelter or staging-area shortcomings after construction has progressed.
Refrigeration capacity is undersized for future growth. Future storage demand can increase or change, and a system designed only for current volume may have limited ability to expand without a costly retrofit.
Relying only on manual temperature logs. Automated, continuous tracking provides faster excursion detection, consistent data capture and audit-ready records, while manual monitoring depends more heavily on human intervention. WHO guidance states that automated and continuous monitoring is preferable and offers reliability advantages compared with manual measurement.
Skipping seasonal considerations where they are relevant. If an area is affected by seasonal temperature variation and the mapping study is carried out only under mild conditions, the study may not demonstrate how the space performs under the relevant seasonal extremes.
Using refrigeration equipment that has not been qualified for its intended use. Suitable equipment must be correctly installed, operated and appropriately qualified to demonstrate that the required storage conditions can be maintained under defined operating conditions. EU GDP requires key equipment and processes to be qualified and/or validated before commencing use, with scope based on documented risk assessment.

Designing for Biologics

The use of biologics makes the design of cold chain warehouses more complicated. Many are more sensitive to temperature excursions than traditional small-molecule drugs, and some require specialised handling for freeze-sensitive formulations, where dropping below the labelled range, even briefly, can be just as damaging as running too warm. In addition to standard vaccines, a biologic facility requires monitoring systems sensitive enough to detect either type of excursion and staff trained to respond according to approved excursion procedures and product-specific stability information.

Bringing It Together at the Design Stage

The performance of a cold chain is strongly influenced at the design stage and should not rely on procedures alone to compensate for engineering design gaps later. Zoning, HVAC and refrigeration capacity, backup power, monitoring infrastructure and control systems need to be designed in concert: a weakness in any one of them can compromise the others.

Pharma Access partners with pharmaceutical manufacturers on facility design to include these requirements from the outset, including cold storage zoning, HVAC and utility design,BMS/EMS and monitoring integration, and the CQV work necessary to take a facility through qualification and temperature mapping before it goes live.

If you are a manufacturer thinking about building a new cold storage facility or expanding an existing one, you should consider current and projected storage volumes, the number of temperature zones required, and the level of redundancy appropriate to the product risk, operational continuity requirements and facility strategy.

A Few Final Thoughts

Pharmaceutical cold chain warehouse design isn’t just refrigeration with some added paperwork. It demands meticulous zoning, HVAC engineering within a defined temperature range, and a mapping process that demonstrates the completed building does in fact perform as designed. When these elements are addressed from the start, ongoing GDP compliance becomes more manageable than trying to correct engineering gaps in a facility that was not designed around cold chain requirements.

Frequently Asked Questions

What temperature range do most vaccines and biologics need in storage?

2°C to 8°C is a common storage range for many vaccines and temperature-sensitive pharmaceutical products. However, storage requirements are product-specific, and some vaccines and biologics require frozen or ultra-cold conditions according to their approved labelling and stability requirements.

How often does a pharmaceutical warehouse need temperature mapping?

Temperature mapping should be completed before a new temperature-controlled storage area is released for use. Subsequent mapping should be based on the monitoring strategy and risk assessment and should also be repeated following significant changes to the facility, temperature-control equipment or storage arrangement. WHO identifies every three years as an example of a possible periodic interval rather than as a universal requirement.

What is the difference between GMP and GDP for cold chain storage?

GMP primarily governs pharmaceutical manufacturing and includes controls for storage activities associated with a manufacturing operation, while GDP focuses on maintaining medicinal-product quality throughout storage and distribution in the supply chain. Depending on the function of the facility and the applicable jurisdiction, a pharmaceutical cold storage warehouse may therefore need to satisfy GMP requirements, GDP requirements, or both.

Why are loading docks a common weak point in cold chain warehouses?

Products are most vulnerable to temperature swings during receiving and shipping when the doors are open and outside air is coming in. Airlock-style anterooms or dock shelters are among the engineering measures that can help limit that exposure, together with appropriate staging, door-control and operating strategies, and it’s difficult to correct such design shortcomings after construction if they were not considered early.

Can an existing warehouse be retrofitted for pharmaceutical cold storage, or does it need to be purpose-built?

Retrofitting is possible depending on the existing structure of the building, the capacity of the utilities, and the infrastructure of the HVAC system. A facility engineering assessment can determine if a retrofit meets GDP requirements or if a purpose-built facility makes more sense.

17/09/202606/10/2026

Cleaning Validation Limits in Pharma: HBEL, PDE and MACO Explained

Not so long ago, much of pharma cleaning validation was based on a simple rule of thumb: 10 ppm, or one-thousandth of the minimum therapeutic dose, and call it a day. The industry has since moved away from relying on these fixed criteria as the sole scientific basis for establishing cleaning limits. HBEL- and PDE-based science now provides the scientific foundation for establishing residue limits, particularly for products manufactured in shared facilities.

In this post, we’re going to peel back the layers of what HBEL and PDE actually mean, how they feed into the MACO calculation that determines your real-world cleaning limits, and what all of this means for facility design. We’ll keep things simple and avoid the heavy toxicology maths when we can.

Why Cleaning Validation Limits Changed

Cleaning validation is done to show that the equipment used to make one product does not pass significant residue on to the next product made on the same line. For decades, the industry has applied arbitrary cut-offs like the 10 ppm rule or the 1/1000th minimum therapeutic dose method. These were easy to use but were not based on the real toxicology of the substance in question and could just as easily overestimate the risk for one compound and underestimate it for another.

Regulatory expectations have moved away from relying on that approach alone. The EMA published its guideline on the setting of health-based exposure limits for shared facilities in 2014, and since then, PIC/S and WHO guidance has also incorporated science- and risk-based approaches to establishing health-based and carryover limits. That change is why HBEL and PDE are now central to the scientific basis used for establishing cleaning-validation limits in shared pharmaceutical facilities.

What Is HBEL Pharmaceutical Guidance Actually Asking For?

HBEL stands for Health-Based Exposure Limit. HBEL pharmaceutical guidance requires that for each relevant medicinal product or residue that may result in cross-contamination, a scientifically based exposure limit be determined for the specific toxicological profile of the compound in question, and not a general formula applied equally to all.

The usual way to get an HBEL is to first determine an appropriate toxicological point of departure, such as a NOAEL (No Observed Adverse Effect Level), where applicable, for the key toxicological effect of a substance, then apply appropriate adjustment factors to take into account the differences between the conditions of the test and real-life human exposure. And this is no trivial desk calculation. This requires real toxicological expertise, and the underlying data needs to be reassessed periodically and when relevant new safety information becomes available the life cycle of a product.

PDE Cleaning Validation: The Practical Output of HBEL

Once an HBEL has been established, it is set out in a defined, usable form.In pharmaceutical manufacturing, a commonly used form of HBEL is the Permitted Daily Exposure (PDE) value, while Acceptable Daily Exposure (ADE) is another term used within industry for a health-based exposure limit. The PDE cleaning validation work is limited to the Permitted Daily Exposure value, which is sometimes known as the Acceptable Daily Exposure (ADE) depending on the terminology a company prefers to use. The PDE is the maximum daily exposure to a residual substance that is considered to be without adverse health effects over a lifetime of exposure.

The PDE value is used by cleaning validation specialists for decision-making. It defines a health-based daily exposure value for the residual substance; it does not, by itself, define how much residue may remain on equipment. The PDE is subsequently used with manufacturing and dosing information to derive a carryover limit such as MACO.

From PDE to MACO: How the Numbers Actually Work

This is where the science becomes a real cleaning limit a technician can test to. The pharma teams take the PDE and relevant manufacturing parameters to calculate the Maximum Allowable Carryover, which represents the highest allowable residue level from one product that can carry over into the next product under the defined manufacturing scenario without exceeding the established health-based exposure limit.

Often the calculation is done with a version like this:

MACO = (PDE of prev product X smallest batch size of next product) / largest daily dose of next product

Put simply, the formula looks like this: Given a health-based exposure limit of the previous product residue and the maximum dose of the next product a patient could potentially receive in a day, what is the maximum residue that could theoretically remain on the equipment before exceeding the established health-based exposure threshold? Once MACO is established in terms of total mass, it is typically translated to more practical, testable numbers, such as mg/cm² of equipment surface or a concentration limit in a rinse sample. This conversion should account for factors such as shared product-contact surface area, sampling area, rinse volume and sampling recovery, as applicable.

MACO represents a calculated health-based carryover limit for a defined manufacturing scenario. Routine cleaning acceptance or alert limits may be established at lower levels based on process capability, validated cleaning performance and Quality Risk Management rather than routinely operating at the MACO boundary.

If the shared facility makes more than one dosage form (e.g., oral, topical, or ophthalmic products), then the PDE derivation must consider the relevant routes of patient exposure, and route-specific HBELs or scientifically justified route-to-route extrapolation may be required where appropriate for the MACO calculation. That science- and risk-based approach helps ensure that the selected exposure limit remains protective for the relevant route of patient exposure.European Medicines Agency (EMA)

HPAPI Cleaning Validation: Where the Stakes Get Higher

With highly potent compounds, this science is nowhere more important. The margins for HPAPI cleaning validation are much tighter than for standard cleaning work because highly potent active pharmaceutical ingredients can cause harmful effects at very low levels of exposure. The PDE of an HPAPI might be in the microgram or even nanogram range, leaving little to no margin for error in the resultant MACO limit.

This narrower margin has direct implications for the way a facility is built and run. The stringency of the PDE and associated MACO values will directly impact decisions on HPAPI facility design, including dedicated vs. shared equipment, containment strategy, and cleaning method selection. The HPAPI facility design done right the first time means the containment strategy and the cleaning validation strategy are solved together and not added on to each other at a later stage. In some cases, an HBEL assessment combined with Quality Risk Management may demonstrate that shared equipment cannot provide adequate and reliable control of carryover for a specific compound, leading to dedicated equipment, segregated processing or other appropriate technical and organisational controls.

Cleaning Method Selection Follows the Numbers

The establishment of MACO limits directly impacts the selection of cleaning methods and the degree of validation required for a facility.

Manual cleaning may be acceptable where the cleaning process can be adequately controlled and validated, but generally demands careful consideration of operator variability and other factors influencing cleaning effectiveness.
Automated Clean-in-Place (CIP) systems provide more consistent and repeatable cleaning performance, and this can become particularly important where stringent cleaning limits must be consistently achieved.
Where an HBEL and cleaning-risk assessment indicates that shared equipment cannot reliably achieve the required carryover control, dedicated equipment or other appropriate measures may be required.
For verification techniques such as swab sampling and rinse sampling, the analytical method must have sufficient sensitivity for the acceptance limit being tested. Total Organic Carbon (TOC) may also be used as a representative, non-specific parameter where scientifically justified and sufficiently sensitive; very low residue limits may require an appropriately sensitive substance-specific analytical method.PIC/S GMP Guide

Brownfield Pharma Upgrades and Cleaning Validation

These limits are not just a new-build issue. Brownfield Pharma upgrades that add a new product to an existing shared facility must trigger a change-control and risk-based impact assessment of the existing HBEL, product/equipment matrix, MACO and cleaning-validation strategy for the products sharing that equipment, not only the new product being introduced. Adding a highly potent compound to a facility that was only handling conventional products can introduce a new worst-case product and significantly tighten the relevant product-to-product carryover limits, sometimes necessitating a switch to dedicated equipment or additional containment measures not originally part of the facility design.

This is one of the reasons why brownfield projects require careful upfront risk assessment prior to the start of construction. For example, a new product may have an HBEL and risk profile that, following Quality Risk Management, indicates a need for equipment dedication that the existing facility layout does not allow. Discovering this mid-project results in expensive redesign work that a thorough HBEL review at the planning stage would have caught early.

Building Cleaning Validation Into Facility Design From the Start

What this all shows most clearly is that cleaning validation is not something you figure out once you build a facility. HBEL, PDE, and MACO decisions influence the selection of equipment, the layout of rooms, and the containment approach long before the first validation protocol is written.

At Pharma Access, our engineering and CQV teams integrate approved cleaning-validation, containment and operational requirements into facility design from the concept stage, whether that’s specifying dedicated equipment for a highly potent product line or designing a shared facility layout that can support the CIP systems needed to hit tight MACO limits reliably. When these requirements are addressed correctly from the start, facilities can avoid expensive equipment changes and layout modifications that may otherwise arise when cleaning-validation gaps are identified after construction has begun. You can read more about our approach on the Pharma Access about page.

Wrapping Up

Modern cleaning validation approaches based on HBELs and PDEs are far beyond arbitrary rules of thumb. HBEL and PDE bring real toxicological science into the process, and the resulting MACO calculation provides facilities with a defensible, patient-safety-based carryover limit for a defined manufacturing scenario that they can validate against. But for very highly potent compounds and brownfield projects adding new products to shared equipment, getting the science right early in the design phase is typically more cost-effective than identifying a gap after construction is finished.World Health Organization (WHO)

FAQs

What is the difference between HBEL and PDE?

HBEL is a more generic term for health-based exposure limits. PDE (Permitted Daily Exposure) is a type of health-based exposure limit derived through a structured scientific evaluation of pharmacological and toxicological data that defines a daily exposure considered unlikely to cause adverse health effects.

How is MACO calculated from a PDE value?

A common formula is to multiply the PDE of the previous product by the smallest batch size of the next product and divide by the largest daily dose of the next product to give the maximum carryover in mass terms.

Why do HPAPIs need stricter cleaning validation limits?

Highly potent compounds can cause adverse effects at very low levels of exposure. The PDE values of highly potent compounds are often very low. This results in a very strict MACO limit, leaving little margin of error in the methods of cleaning and detection.

Does adding a new product to an existing facility require redoing cleaning validation?

Introducing a new product to shared equipment should trigger a documented change-control and risk-based assessment of its potential impact on the existing cleaning-validation programme. HBEL information, worst-case product selection, relevant MACO calculations and the existing cleaning strategy should be reviewed as applicable rather than assuming that one lowest limit automatically applies to the entire line.

Can shared equipment always be used if the MACO limit is met on paper?

Not necessarily. While a calculated MACO limit may be technically achievable, the acceptability of shared equipment must also consider Quality Risk Management, cleanability, containment, equipment design, analytical capability and the ability of the validated cleaning process to consistently control carryover. Where adequate control cannot be demonstrated, dedicated equipment, segregation or other appropriate measures may be required.

10/09/202606/10/2026

IQ, OQ and PQ in Pharma: A Practical Facility & Equipment Qualification Guide

If you work anywhere near a pharma manufacturing floor, you have heard these three letters thrown around constantly: IQ, OQ, PQ. They sound like alphabet soup until you actually need to install a new tablet press or bring a filling line online, and suddenly they are the only thing standing between your equipment and production. No one involved in facility projects can afford not to understand IQ, OQ, and PQ pharmaceutical industry requirements. That’s the core of how manufacturers demonstrate that equipment, facilities, utilities and systems are suitable for their intended use and regulators assess the documented evidence supporting that qualification.

This post goes through what each stage covers, how they work together, and what real IQ, OQ, and PQ HVAC pharmaceutical industry work looks like on the ground. We’ll try to keep it simple and avoid dense regulatory language where possible.

What Do IQ, OQ, and PQ Actually Mean?

Qualification is the documented process that verifies that equipment, systems, or utilities are fit for their intended use. It provides documented evidence that the equipment or system is ready to perform its intended function, not just sitting in the room looking good.

The three core stages are as follows:

Installation Qualification (IQ): Verifies that the equipment is installed properly, utilities are connected correctly, and all documentation and components agree with the approved engineering drawings and specifications.
Operational Qualification (OQ): Tests machine functions like speed, temperature, alarms, interlocks, and control systems to confirm proper operation within defined limits.
Performance Qualification (PQ): Demonstrates that the facility, utility, equipment, or system performs effectively and reproducibly under representative normal operating conditions.

Each step builds on the one before. You can’t skip IQ and go right to OQ, because testing how a machine works isn’t meaningful if it was never verified to be installed properly in the first place. Depending on equipment complexity and the approved qualification strategy, however, IQ and OQ may be performed as a combined IOQ.

DQ: The Step Before IQ

All this happens after most facilities have been through a Design Qualification (DQ) stage.DQ itself is normally preceded by a User Requirements Specification (URS), which defines what the facility, utility, equipment, or system is expected to achieve. DQ makes sure the equipment or system is designed to meet GMP and user requirements before you buy it or before the design is finalised. . For instance, before buying a tablet compression machine, a facility will confirm that the design matches the intended production speed, batch size, and cleaning needs. Getting DQ right early reduces downstream redesign and qualification rework. Catching a design mismatch on paper is much cheaper than catching it after the equipment is already installed.European Commission Qualification and Validation.

DQ IQ OQ PQ Equipment Qualification in Pharma: The Full Sequence

The full sequence for DQ, IQ, OQ, and PQ equipment qualification that pharma teams follow typically progresses from URS and DQ through FAT/SAT, where applicable, followed by IQ, OQ, and PQ. Each stage is logically connected and should be appropriately documented before progression, although stages may be combined or conditional progression may be authorised where scientifically justified and documented.

Installation Qualification (IQ) is the first step. It confirms that:

The equipment conforms to approved engineering drawings and specifications, purchase requirements, and vendor specifications.
Utilities: power, water, and compressed air are connected correctly.
All manuals, drawings, and calibration certificates are available and correct.
The equipment is physically situated in an environment which satisfies its intended operating conditions.
If careful documentation is skipped here, problems may not show up until much later, particularly when records are requested during review or inspection.

Operational Qualification (OQ): OQ tests the actual functions of the equipment. In this stage, it checks things like:

Speed and timing controls are within their specified ranges.
Alarms will fire correctly when conditions are out of range.
Interlocks and safety systems operate as intended.
Control systems maintain set points under varying loads.
Relevant upper and lower operating limits and worst-case conditions are challenged where appropriate.

A lot of real problems get caught at OQ. A machine could be installed perfectly but still not hold temperature within spec, or its alarm could activate outside the specified set point or tolerance. The whole point of the exercise is to find that during OQ, not during a live production run.

Performance Qualification (PQ)

It is the last step and should normally begin when IQ and OQ are both complete. Through PQ, a facility demonstrates with real evidence that its equipment or system performs effectively and reproducibly under representative normal operating conditions and across the intended operating range. For example, a PQ for a tablet press may involve production of full-scale batches or representative production runs, with justified sampling used to evaluate relevant equipment-performance, in-process and product-quality parameters, as applicable.

PQ should not be confused with Process Performance Qualification (PPQ). Equipment PQ demonstrates that a facility, utility, equipment item or system performs as intended under representative operating conditions. PPQ is part of process validation and evaluates whether the commercial manufacturing process, using qualified facilities, utilities and equipment together with trained personnel and established controls, can reproducibly manufacture products meeting its predetermined quality requirements.

IQ OQ PQ Examples: What This Looks Like in Practice

Reading about IQ, OQ and PQ in the abstract is only so helpful. Here are a few concrete IQ OQ PQ examples that illustrate how this plays out for common pharma equipment:

Autoclave: IQ verifies correct installation and utility connections. OQ tests include cycle controls, temperature distribution, pressure control, alarms and interlocks. PQ confirms reproducible cycle performance and heat penetration across defined load configurations, with appropriate biological challenge where applicable.
HVAC system: IQ verifies ductwork, filters, instrumentation and controls installed to specification. OQ checks airflow rates, pressure differentials, environmental controls and alarm response. PQ verifies that the system maintains the required environmental conditions and cleanroom performance under representative operating conditions, as applicable.
Filling line: IQ confirms mechanical installation and utility hookups. OQ tests fill accuracy, speed settings, alarms, interlocks and reject mechanisms across the intended operating range. PQ confirms that under representative production conditions, the line performs consistently over an appropriate operating period, including personnel changes and routine operating interventions where relevant.
Stability chamber: IQ verifies installation and calibration records. OQ verifies temperature and humidity control over the defined operating range. PQ confirms the chamber holds these conditions reliably over an extended period with an appropriate representative load.

Every piece of GMP-impacting pharma equipment gets this same basic treatment, with the scope and depth of qualification scaled according to its risk, complexity, criticality and intended use.

Facility Qualification vs Equipment Qualification

There is a distinction that trips up a lot of people new to this subject, and it’s worth being clear about. Qualification of equipment is specific to individual machines, such as a tablet press or an autoclave. Facility qualification is broader, covering GMP-relevant facilities and supporting systems that support all that equipment together, things like HVAC, water systems, clean utilities, and the overall cleanroom environment.

A successful programme in this area confirms that the building itself, not just the individual pieces of equipment inside, meets the conditions needed for GMP manufacturing. Both approaches have the same DQ, IQ, OQ, and PQ logic, but qualifying the whole building usually takes more time and involves more interconnected systems, as a change in one utility can impact several rooms and processes at the same time.

Why IQ, OQ, and PQ in the Pharmaceutical Industry Matter So Much

Without documented evidence across DQ, IQ, OQ, and PQ, regulators cannot verify that your equipment and facility consistently support GMP manufacturing. This is not a paperwork formality. A pharmaceutical product made using inadequately qualified GMP-critical equipment or systems may introduce real risks for patients, whether it’s inconsistent dosing, contamination, or inadequate control of a sterilisation process.

Regulatory bodies, including the FDA, consider qualification as one of the key activities that must be completed before equipment and utilities are used for commercial-scale Process Performance Qualification and before routine commercial distribution begins.

Common Mistakes Facilities Make With IQ, OQ, and PQ

During qualification work, a handful of recurring issues show up again and again:

You start OQ before IQ is adequately completed or formally released, without a documented combined IOQ or conditional-progression strategy, forcing teams to retest functions once installation gaps are identified late.
Weak or absent DQ documentation, meaning there is no clear baseline against which equipment can be tested during later stages.
Treating PQ as a formality rather than a genuine test under realistic production loads and shift patterns.
Bad change control, where a mid-project equipment substitution or design tweak never makes it back into the qualification protocols.
Disconnected facility and equipment qualification, where HVAC or utility qualification is on a separate track from equipment qualification, creating gaps at the interfaces between them.

Where This Fits Into the Bigger Picture: Commissioning Qualification Validation

IQ, OQ and PQ do not happen in isolation. They sit within the broader commissioning qualification validation framework that governs how a pharma facility is built and brought online. Commissioning provides engineering evidence that systems have been installed, tested and operated in accordance with approved design requirements and design intent. Qualification (DQ, IQ, OQ, and PQ) provides the documented GMP evidence that applicable facilities, utilities, equipment and systems are suitable for their intended purpose. Validation demonstrates that the manufacturing process can consistently deliver product meeting predetermined quality requirements.

Seeing these as one connected lifecycle (rather than three separate handoffs between different teams) is what prevents a facility from finding out about gaps after production has already begun.General Principles and Practices, Guidance for Industry

How This Connects to Facility Design and Construction

Qualification results are determined well in advance of anyone executing a single IQ protocol. The design and construction of a facility will determine the ease with which qualification proceeds. For a more detailed look at how design and construction decisions flow into qualification, our guide to facility design & construction spans the full lifecycle from concept through commissioning and pairs well with the qualification concepts covered here.

Our teams at Pharma Access take design intent through construction and into CQV, so validation protocols are written against decisions made by our own engineers, not recreated after the fact from someone else’s drawings. A big part of that continuity is why DQ, IQ, OQ, and PQ equipment qualification pharma work can maintain clearer traceability from design intent through commissioning and qualification while reducing the risk of late-stage documentation and system-interface gaps. You can read more about our approach on the Pharma Access about page.

Getting IQ, OQ, and PQ Right the First Time

Facilities that treat design and construction decisions, the kind covered in our guide to facility design & construction, as part of the qualification story from day one tend to move through IQ, OQ and PQ with far fewer surprises.

A handful of habits distinguish teams that do well in qualification from those that get stuck:

Write the URS and DQ documentation before finalising equipment procurement so that IQ has a clear approved specification to test against.
Instead of running stages in parallel without a justified qualification strategy, close out each stage or formally authorise progression before starting the next one.
Build realistic PQ scenarios covering an appropriate operating period and representative conditions, including adjustments, stoppages, personnel changes and material replenishment where relevant, not just a single best-case run.
Keep facility and equipment qualification linked, so utility and HVAC qualification corresponds to the equipment schedules that depend on them.
Maintain tight change control throughout the project so that any equipment or design change is reflected immediately in the qualification protocols and associated documentation.

Wrapping Up

Good IQ OQ PQ pharmaceutical industry practice is not a bureaucratic hoop to jump through in manufacturing. They are the structured trail of evidence that proves that your equipment and facility actually do what they were designed to do, consistently and safely. Get the sequence right, document thoroughly, and treat facility and equipment qualification as one connected process, and your project is better positioned for inspection readiness while reducing the risk of qualification-related rework.

FAQs

What is the difference between IQ, OQ, and PQ?

IQ verifies the equipment is installed correctly. OQ tests that it runs within defined limits. PQ confirms that the equipment or system performs effectively and reproducibly under representative operating conditions. The stages normally progress logically, although qualification activities may be combined or progression may be conditionally authorised where appropriately justified and documented.

What does DQ mean, and why does it come before IQ?

DQ is Design Qualification. It ensures the equipment’s design conforms to GMP and the approved URS before procurement or design finalisation, providing IQ with a clear specification to check installation against later.

Can any of these qualification stages be skipped for simple equipment?

The rigour can scale with risk, but qualification activities may be combined or simplified where justified by risk, complexity and criticality. What should not be omitted for GMP-impacting equipment is adequate documented evidence that the equipment is suitable for its intended use.

What is the difference between equipment qualification and facility qualification?

Equipment qualification is done on a per-machine basis. The qualification of the facility is the qualification of the broader building systems, such as HVAC and utilities, that support all the equipment as a whole. They both follow the same DQ, IQ, OQ, and PQ approach, just at a different scale.

How long does IQ OQ PQ typically take for a new facility?

There is no universal duration for IQ, OQ and PQ on a new pharmaceutical facility. The timeline depends on facility size, the number and complexity of systems, equipment criticality, FAT/SAT strategy, documentation readiness, qualification sequencing, deviations and the overall CQV execution plan.

10/09/202613/10/2026

RABS vs Isolators for Aseptic Processing: Design, Annex 1 & Qualification Compared

If your facility fills sterile products, you’ve likely been faced with this decision at some point: RABS vs isolators. Both systems are designed to reduce contamination risks associated with personnel and direct human intervention during filling, but they get there in very different ways – and that difference shows up in your design and construction cost, your cleanroom grading, and how your facility gets qualified.

This post explains how the two technologies differ, what the current EU regulatory guidance requires of each, and what qualification looks like once the system is installed. We won’t dive deep into the engineering details; we’ll keep it simple.

What Are RABS and Isolators, in Plain Terms?

An RABS, or Restricted Access Barrier System, is effectively a physical barrier made around a filling line, with gloved ports through which operators can reach when needed. In normal production, the barrier is closed, but depending on the design, doors are rarely opened and only under strictly predefined conditions. It provides an enclosed, but not fully sealed, environment that separates the Grade A processing zone from the surrounding cleanroom.

An isolator is more. It’s a self-contained, enclosed system that provides continuous isolation of its interior from the surrounding environment, with a controlled Grade A work zone and a reproducible bio-decontamination process. Operators only interact with the process through glove ports or half-suits. The isolator provides continuous separation from the surrounding cleanroom, allowing lower background cleanroom grades where justified through risk assessment and the Contamination Control Strategy (CCS).

The main difference is that RABS provides an enclosed but not fully sealed barrier between the aseptic process and the surrounding cleanroom. Isolators provide continuous isolation of the internal Grade A environment from the external environment.

How EU GMP Annex 1 Treats RABS vs Isolators

The 2022 update to this guidance changed the expectation of how regulators want manufacturers to think about barrier technology. Cleanrooms, laminar flow hoods and open processing were common enough before this revision. The revised annex places greater emphasis on appropriate barrier technologies and contamination-control measures for protecting critical aseptic processing zones.

The use of RABS and isolators in the maintenance of the required conditions and reduction of microbial contamination associated with direct human intervention in the critical zone is described as beneficial in this guidance. It states that the use of these should be considered as part of the Contamination Control Strategy (CCS) and that any alternative approach needs justification. In practice, that means a manufacturer who chooses not to use one of these systems now has to justify the decision, rather than the other way around.

EU GMP Annex 1 RABS Requirements

The annexe is specific as to what a RABS installation must show. It should be maintained at Grade A conditions with unidirectional airflow and first air protection in the critical zone, and the background environment around an RABS used for aseptic processing needs to be at least Grade B. That Grade B requirement is a big part of what makes RABS more expensive to operate than it might first appear, since the entire surrounding room has to be built and maintained to that classification.

What Annex 1 Says About Isolators

Isolators are handled differently because they provide continuous isolation of the interior from the external environment. Isolators provide continuous isolation of the interior from the external environment, and the annex describes two types of isolators: closed and open. The difference between the two is the manner in which materials move in and out during operation. The background classification requirements are different from those for RABS: the surrounding room for an open isolator is generally required to be at least Grade C, and for a closed isolator at least Grade D. The final background classification should be based on risk assessment and justified within the CCS, and a higher grade may be required where additional process risks are identified. That is a much lower background classification requirement than the Grade B environment a RABS installation requires.

Comparing RABS and Isolators Side by Side

Here’s a quick summary of the main differences that matter for facility design.

RABS Grade: Minimum Grade B background required. Isolator background: Depending on the design, open isolators generally require a minimum Grade C background, while closed isolators require a minimum Grade D background, subject to risk assessment and CCS justification.
Separation level: RABS has an enclosed but not fully sealed barrier, with doors rarely opened and only under strictly predefined conditions. Isolators provide continuous isolation of the internal Grade A work zone from the external environment.
Air handling: RABS maintains Grade A conditions with unidirectional airflow, first air protection and positive airflow from the critical zone toward the supporting background environment. Isolators maintain Grade A conditions within the internal work zone, with airflow requirements depending on whether the isolator is open or closed and on the process design.
Decontamination: Isolators require an automated, validated and controlled interior bio-decontamination process using a suitable sporicidal agent. RABS require validated routine sporicidal disinfection of the interior surfaces to ensure a suitable environment for aseptic processing.
Cost of capital: Isolators are often more expensive to purchase up front because they are self-contained and automated. Although the initial cost of RABS might be lower, the continued operating costs of Grade B rooms could be higher.
Flexibility: RABS systems are often easier to retrofit into existing filling lines. Isolators can require greater integration with the filling line, transfer systems, utilities, controls and facility design, although retrofit feasibility depends on the existing installation.

Know More : European Commission Qualification and Validation

Aseptic Barrier Systems and Qualification: What Changes

RABS and isolators are both forms of aseptic barrier systems. However, the qualification of each is slightly different, based on the way each interacts with the surrounding facility.

RABS Qualification

To be able to qualify a RABS installation, the interaction between the barrier and the Grade B room surrounding it has to be considered. This means that airflow visualisation studies have to be performed to show that unidirectional flow is maintained and to demonstrate the absence of air ingress during interventions, including door openings where applicable. Since it is easy to transfer contamination between the RABS and the surrounding Grade B space, environmental monitoring needs to be performed within the RABS and the surrounding Grade B space as defined by the facility’s environmental and process monitoring strategy.

Isolator Qualification

The qualification of an isolator is often more concentrated on the decontamination cycle, as this is the step that establishes the validated bio-decontaminated condition inside the unit before aseptic processing. Qualification protocols usually check that the vapour-phase decontamination cycle consistently achieves its predefined and validated acceptance criteria and include leak testing to confirm the isolator maintains its integrity at defined intervals. This qualification work places relatively less emphasis on the background room performance and more on the isolator’s own containment and decontamination systems because the surrounding room requirement is lower.

Glove-system integrity is also an important part of isolator control. Annex 1 expects leak testing of isolator glove systems at defined intervals and generally at the beginning and end of each batch or campaign, with additional testing where required by the validated campaign length.

Aseptic Process Simulations for Both Systems

With Annex 1, there are heightened expectations for aseptic process simulations across the board, no matter the barrier technology a facility uses. The updated guidance introduces a tighter action level for Grade A viable contamination, with the Grade A action limit defined as “no growth” and any growth requiring investigation. Initial qualification must be performed on RABS and isolator lines with at least three consecutive satisfactory simulations covering all working shifts in which the aseptic process may occur, followed by periodic revalidation, typically twice per year for each aseptic process, each filling line and each shift. Each operator should also participate in at least one successful APS annually.

Know More : Manufacture of Sterile Medicinal Products

Which System Should Your Facility Choose?

There is no single answer that fits all, and EU GMP Annex 1 does not establish a hierarchy that requires isolators to be selected over RABS. The appropriate barrier technology should instead be justified through the CCS and quality-risk-management approach. But the practical answer tends to boil down to a few things:

New construction or retrofit? RABS can generally be added to an existing filling line with less extensive facility integration in some applications, although the feasibility depends on the existing line and cleanroom design.
What is the risk level of your product? Processes involving complex or frequent interventions, challenging aseptic transfers or other elevated contamination risks may benefit from the greater degree of separation provided by isolator technology. However, product modality alone should not determine the barrier-system selection.
What is the operational maturity of your team? The decontamination cycle and integrity of the gloves require more detailed management, and the training of the staff and procedures must be in line with this level of detail.
What does your budget and schedule allow? Isolators tend to be more expensive initially, but they can reduce the ongoing costs of maintaining a Grade B environment.

For existing facilities, a phased barrier-technology strategy may be considered, with RABS retained or implemented where technically appropriate and isolator technology evaluated for new lines or major expansions based on the process and facility requirements.

Designing Your Facility Around the Right Barrier Choice

The decision to employ RABS or isolators is never isolated. It drives HVAC sizing, room classification, growing requirements, and even the square footage the aseptic suite needs.It can also influence material-transfer strategy, intervention design, environmental monitoring, decontamination systems and the overall CQV scope. Getting this decision right at the concept design stage saves the costly rework that comes from discovering mid-construction that the room was built for the wrong background grade.

At Pharma Access, our engineering design and CQV teams partner with clients through this decision from the earliest planning stage, considering product risk, facility layout, and long-term operational plans before committing to an isolator- or RABS-based approach. We make that decision and take it through cleanroom design, HVAC, and qualification as one connected process so the facility that’s built is aligned with the aseptic process it needs to support. Read more about our approach on the Pharma Access about page.

Wrapping Up

Both RABS and isolators are there to solve the same underlying problem, which is keeping people away from sterile products during filling. RABS can offer lower initial barrier-equipment cost and greater retrofit flexibility in suitable applications but still requires a Grade B background and careful qualification of the barrier system and its interaction with the surrounding environment.

Isolators provide continuous separation, lower background grade requirements, and qualification that is focused strongly on barrier integrity and validated bio-decontamination performance. Annex 1 makes clear that RABS or isolators should be considered as part of the CCS, while alternative approaches need to be justified.

FAQs

What is the main difference between RABS and isolators?

RABS is an enclosed but not fully sealed barrier system whose doors are rarely opened and only under strictly predefined conditions, and usually needs a Grade B background room. Isolators are enclosed systems providing continuous isolation of their internal Grade A work zone from the surrounding environment and can often operate in a Grade C or D environment depending on whether the isolator is open or closed and on the CCS risk assessment.

Does EU GMP Annex 1 require isolators over RABS?

Not exactly. Annex 1 states that RABS or isolators should be considered in the Contamination Control Strategy, with justification for alternatives. It does not establish isolators as a regulatory requirement over RABS; the selection should be based on process risk, barrier design and the CCS.

Why do isolators need a lower background cleanroom grade than RABS?

Isolators provide continuous isolation of their internal Grade A environment from the surrounding cleanroom, and so lower background grades can be justified based on the isolator design and risk assessment. RABS are enclosed but not fully sealed, so Annex 1 requires a minimum Grade B background for RABS used for aseptic processing.

What does isolator qualification focus on that RABS qualification does not?

Isolator qualification is very focused on the decontamination cycle, checking that the validated bio-decontamination process consistently operates within its defined cycle parameters and achieves established acceptance criteria, together with isolator and glove-system integrity testing. RABS qualification is more about maintaining Grade A conditions, airflow performance and demonstrating the absence of air ingress during interventions, including door openings where applicable, together with the required Grade B background.

Can an existing RABS line be converted to an isolator later?

It can be done, but typically at a cost, as isolators may require significant integration with the existing filling line, transfer systems, HVAC, utilities, automation and room configuration. Many facilities therefore evaluate isolator retrofit feasibility against installing the technology as part of a new line or major expansion.

19/08/202619/08/2026

What is the Slope Required for a Pharmaceutical Water System?

If you have ever watched a site team review a piping drawing with an engineer, slope is usually one of the details that gets close attention. It sounds like a small detail, but in a pharmaceutical water system, the wrong slope can leave residual water in low points when the system is intentionally drained, increasing microbiological and sanitization risk. Getting this one detail right supports drainability and hygienic system performance.

This post explains what slope actually means for pharma piping, what guidance engineers commonly follow, and why it matters so much for water quality. We will keep the explanation simple and skip the heavy engineering language where we can.

Quick answer: WHO GMP guidance recommends that pharmaceutical Purified Water (PW) and bulk Water for Injection (BWFI) systems be installed to promote drainability with a minimum recommended slope of 1:100 where full drainage is required. That equals a 1% fall, or approximately 10 mm per metre of pipe. The final project requirement should still be defined in the approved design documents and specifications.

Why Slope Matters in a Pharmaceutical Water System

Slope is the gradient at which a pipe tilts downward so water can drain from the line instead of collecting at unintended low points. In a Purified Water (PW) or Water for Injection (WFI) system, that pooling is not just a maintenance headache. It is a potential microbiological-control risk. WHO specifically recommends hygienic design, minimization of dead legs, continuous circulation and installation that permits full drainage where required.

Here is why. Pharmaceutical water systems get sanitized according to defined procedures, which may use thermal and/or chemical sanitization depending on the system design. If a section of pipe cannot drain fully, leftover water may remain in low points when that part of the system is intentionally drained for sanitization, shutdown, maintenance or other activities. Standing water can create conditions that support microbial proliferation, which is why hygienic design aims to minimize stagnation. WHO identifies chemical and thermal sanitization, continuous circulation and prevention of stagnant water as important microbiological-control measures.

During normal operation, PW and BWFI distribution systems are generally designed as recirculating loops rather than systems that simply sit full of stationary water. WHO recommends continuous circulation for BPW and BWFI distribution systems unless a non-recirculating design is appropriately justified.

What Slope Do Pharma Water Systems Actually Need?

There is no single fixed number written into every pharmaceutical regulation worldwide, but WHO GMP guidance provides a clear drainability recommendation, while project-specific standards and specifications may add further requirements.

WHO GMP guideline: WHO recommends that PW and WFI systems be installed to promote drainability with a minimum slope of 1:100. It also gives a guidance figure of not less than 1:100 where pipework needs to allow full drainage.
Metric equivalent: A slope of 1:100 means a 1% fall, or 10 millimetres of vertical drop for every metre of horizontal pipe run.
Imperial equivalent: A 1:100 slope is approximately equivalent to 1/8 inch of fall per foot. A 1/4-inch-per-foot slope is approximately 2%, so 1/8 to 1/4 inch per foot should not be described as a direct equivalent of 1:100.
ASME BPE context: ASME BPE is an important hygienic-design standard used in bioprocessing and pharmaceutical applications. The current edition is ASME BPE-2026, and the slope criteria used on a project should be confirmed against the edition and design specification adopted for that project rather than treating 1/8 to 1/4 inch per foot as a universal ASME requirement.

The exact number your project uses will depend on the applicable standard, system layout, drainability requirement, equipment interfaces, pipe routing and the approved engineering specification. What stays constant across all of them is the goal: where full drainage is required, the piping should be installed so that unintended low points and trapped water are avoided. WHO explicitly identifies full drainage and a guidance slope of not less than 1:100 as water-system design considerations.

Steps to Confirm Correct Slope During Installation

Getting the slope right on paper is one thing. Confirming it on the actual installed piping is where problems often get caught. Here is a simple sequence most teams follow:

Review the design drawings. Confirm the required slope is called out clearly for every relevant pipe run.
Install with slope in mind. Fit hangers and supports at intervals that hold the intended drop, not just a level line.
Measure the installed slope. Use the approved slope-verification method and suitable calibrated measurement equipment at multiple points along the run.
Document the readings. Record actual slope values against the design specification for each section as part of the applicable construction, commissioning or qualification documentation..
Flag and correct deviations. Any section that falls short of the specified acceptance criterion minimum slope gets adjusted before the system moves into qualification.
Re-verify after any rework. Recheck slope any time a section of piping is modified, repaired, or replaced.

WHO requires pharmaceutical water systems to be appropriately qualified and validated, requires commissioning activities to be documented, and identifies drawings, on-site test records, weld records and other evidence of system qualification as important documentation.

Common Problems That Come From Poor Slope

A handful of recurring issues show up when slope or the wider hygienic piping design gets overlooked during design or installation:

Dead legs. Sections of pipe or branch arrangements with inadequate circulation, often near tees or valve branches, where water may stagnate. Dead-leg control is a separate hygienic-design requirement and should not be treated as something that slope alone can correct. WHO recommends zero-dead-leg diaphragm valves where possible and minimizing dead legs elsewhere.
Low points and sags. Pipe runs that were not properly supported can sag over time, creating pockets that trap water even if the original slope was correct.
Poor fitting selection. Standard fittings and valves are not always designed with drainability in mind, and the wrong choice or orientation can undo an otherwise correct slope.
Rough interior surfaces. Poor internal surface condition can make hygienic cleaning more difficult and provide additional retention or attachment sites for contamination. It should not simply be described as slowing the bulk movement of water. WHO states that internal finishes for PW and BWFI systems should be smooth and gives specific sanitary-design considerations for sample valves and related components.

How Slope Connects to the Bigger Picture of Water System Design

Slope is one piece of a much larger design puzzle for a pharmaceutical water system. It works alongside pipe material selection, welding quality, valve placement, hygienic fittings, continuous circulation, sanitization strategy, instrumentation, and storage tank design to keep the whole distribution loop under microbiological control. Get the slope right but ignore dead legs, and you have only solved part of the problem.

Surface finish plays a supporting role too. A pipe with a poor internal finish can be more difficult to clean and can provide additional sites for material retention or microbial attachment, even when the pipe has been correctly installed for drainage. That is why most pharma piping specifications call out both a slope requirement and appropriate hygienic surface-finish requirements, since one without the other does not provide a complete hygienic-design strategy. WHO recommends smooth internal finishes and sanitary design for PW and WFI systems.

This is where sound Pharma Project Management Services make a real difference. Coordinating piping design, installation, and commissioning and qualification as one connected process, rather than as separate handoffs between contractors, cuts down on the rework that happens when a slope issue only gets caught after the system is already built and insulated.

Slope, Effluent, and the Full Water Lifecycle

Water in a pharma facility does not disappear once it leaves the purified water loop. Rinse water, cleaning water, and process water eventually need to go somewhere, and that is where pharma effluent treatment solutions come into the picture. A facility that gets its water generation and distribution piping right on the front end still needs a plan for treating and discharging wastewater responsibly on the back end.

Appropriate drainage gradients also matter in wastewater piping, although the design criteria are different from those used for hygienic PW and WFI distribution systems. Effluent lines with weak slope or hidden low points can back up or hold waste longer than intended, adding load to the treatment system downstream. Thinking about both sides of the water lifecycle at the design stage avoids costly retrofits later.

The 1:100 recommendation discussed in this article applies to pharmaceutical water-system drainability and should not automatically be copied into effluent-piping design. Wastewater gradients should be determined from the applicable hydraulic design, pipe characteristics, effluent properties, layout and project requirements.

Why Work with Experienced Pharma Consultants in India

Slope requirements sound simple on paper, but getting them right across a full facility, hundreds of meters of piping, dozens of branch connections, and multiple storage points, takes real design and construction experience. Working with established Pharma Consultants in India means your piping layout can be reviewed as part of the wider clean-utility and facility-engineering design instead of treating slope as an isolated installation detail.

At Pharma Access, our engineering design team handles mechanical and utility system design, including Purified Water, Water for Injection and associated clean-utility integration, as part of full facility projects across India and other markets. Pharma Access’s clean-utility capabilities specifically include PW and WFI systems. We build slope, drainability, and qualification considerations into the design from day one instead of treating them as an afterthought during construction. This integrated approach connects utility engineering with piping coordination, construction, project management and CQV requirements. Pharma Access’s wider project approach covers engineering and project-management activities across pharmaceutical facilities in India and international markets.

You can learn more about our approach to pharma facility projects on the Pharma Access about page.

Wrapping Up

Slope might sound like a minor detail on a piping drawing, but in a pharmaceutical water system, it directly affects drainability and the ability to avoid unintended water retention when the system needs to be drained. For PW and WFI systems where drainability is required, WHO recommends a minimum slope of 1:100, equivalent to a 1% fall or approximately 10 mm per metre.

Verify it during installation, and keep low points, poor valve orientation and stagnation-prone dead legs out of the design. Get those basics right, and the rest of your water system has a much better chance of moving efficiently through commissioning and qualification without avoidable piping rework.

FAQs

What slope is required for pharmaceutical water piping?

WHO GMP guidance recommends a minimum slope of 1:100 where pharmaceutical PW and WFI piping is intended to provide full drainage. This equals a 1% fall, or approximately 10 mm for every metre of pipe. The exact figure and acceptance criteria should always be confirmed against the applicable project design specification and adopted standards.

Why does slope matter so much in a purified water system?

Without proper slope, water can remain in unintended low points when the piping is drained instead of draining fully. Standing water can create conditions that increase microbiological risk, which puts water quality control at risk. During normal operation, circulation is also important; WHO recommends continuous circulation for BPW and BWFI distribution loops unless an alternative system is appropriately justified.

What is a dead leg, and why is it a problem?

A dead leg is a section of pipe, often near a valve or branch, where circulation is inadequate and water may stagnate. These spots are more difficult to maintain under effective microbiological control and therefore need to be minimized through hygienic design. WHO recommends the use of zero-dead-leg diaphragm valves where possible and minimizing dead legs elsewhere.

How is pipe slope checked after installation?

Technicians use an approved slope-verification method with suitable calibrated measurement equipment at several points along each run, then compare the readings against the design drawings and approved acceptance criteria to confirm the pipe meets the required drop. The verification should be documented according to the project’s construction, commissioning and qualification procedures. WHO requires documented commissioning and appropriate qualification of pharmaceutical water systems.

Does slope affect wastewater and effluent systems too?

Yes. Appropriate drainage gradients are also important for wastewater and effluent piping, but the design criteria are not automatically the same as the 1:100 guidance used for drainable pharmaceutical water systems. Poor slope in effluent lines can cause backups or incomplete drainage, adding strain to downstream treatment systems. The correct effluent-piping gradient should therefore come from the hydraulic and project-specific design requirements.

13/08/202613/08/2026

Cleanroom Validation Procedure According to ISO Guidelines

If you run a pharma facility, you already know a cleanroom is more than a clean-looking room. It is a controlled space where airborne particle concentrations and other critical environmental parameters are measured, monitored, and maintained within defined limits. Getting that control right is what a cleanroom validation procedure is all about, and ISO 14644 provides the standardized framework for cleanroom classification, testing, and monitoring.

This post walks through what that process actually involves, how ISO 14644 fits into it, and what to expect at each stage. We will keep the language simple, because this topic becomes technical quickly.

What Is a Cleanroom Validation Procedure?

A cleanroom validation procedure is commonly used to describe the documented qualification process of proving that a controlled environment does what it is designed to do. That means checking air cleanliness, airflow patterns, pressure differences, temperature, humidity, and filter performance, then recording the results against a defined standard. In GMP terminology, facilities, utilities, equipment, and systems are generally qualified, while manufacturing processes are validated. Cleanroom classification is one part of the broader cleanroom qualification process. https://picscheme.org/docview/8881

For pharma manufacturers, this is not optional paperwork. FDA guidance and EU/PIC/S GMP requirements expect documented evidence that pharmaceutical cleanrooms maintain their required environmental conditions and classification, including defined at-rest and in-operation conditions where applicable.

Why ISO 14644 Matters

ISO 14644 is the standard series that pharma teams rely on for cleanroom classification, testing, and monitoring. It sets the rules for classifying air cleanliness based on the concentration of airborne particles in cleanrooms, clean zones, and separative devices. Within the series, ISO 14644-1 covers classification by particle concentration, ISO 14644-2 addresses monitoring, ISO 14644-3 provides cleanroom test methods, ISO 14644-4 covers design, construction, and start-up, and ISO 14644-5:2025 addresses cleanroom operations.

Here is why this matters day to day. Without a common standard, every facility would test differently, and no two audit reports would mean the same thing. ISO 14644 gives everyone, from your engineering team to your regulator, a common technical framework for assessing airborne particulate cleanliness.

ISO Classes at a Glance

ISO 14644-1:2015 defines nine air cleanliness classes, from ISO 1 to ISO 9, based on the maximum number of airborne particles allowed per cubic meter at particle sizes within the classification range of 0.1 to 5 microns. A few points worth knowing:

ISO Class 5 conditions are commonly applied to critical areas for aseptic processing, subject to the applicable GMP framework.
ISO Class 7 and ISO Class 8 environments may be used for supporting or less critical activities depending on the process and regulatory requirements.
ISO Classes 5 through 8 are commonly encountered across pharmaceutical and biologic facilities, depending on the manufacturing activity and contamination-control requirements.
An M descriptor can be used separately to record macroparticles larger than 5 micrometers.

ISO 14644-1 classifies non-viable airborne particle concentration; it does not by itself characterize the viable, microbiological, chemical, or radiological nature of those particles or establish complete GMP suitability.

Lower numbers mean stricter limits. An ISO 5 room allows far fewer particles than an ISO 8 room.

The Three Qualification Stages

Within the broader qualification lifecycle, many cleanroom projects move through three core execution stages: IQ, OQ, and PQ. Earlier lifecycle activities include the User Requirements Specification (URS) and Design Qualification (DQ), with Factory Acceptance Testing (FAT) and Site Acceptance Testing (SAT) used where applicable. Think of them as building blocks. Each stage provides documented evidence supporting the stages that follow.

Installation Qualification (IQ)

This stage confirms the room was built and its systems were installed the way it was designed. It checks that components such as HVAC units, HEPA filters, walls, ceilings, doors, and controls have been installed according to the approved design, engineering specifications, and predefined criteria. If a filter is in the wrong spot or a door does not seal, IQ catches it before production ever starts.

Operational Qualification (OQ)

Once installation is confirmed, OQ checks that the systems work as intended throughout their defined operating ranges and applicable challenge conditions. For cleanroom qualification, applicable testing may cover particle counts, airflow, pressure differentials, filter integrity, and other defined environmental parameters.

Performance Qualification (PQ)

PQ confirms that the cleanroom and its supporting systems can perform effectively and reproducibly under intended operating conditions, including when personnel and routine processes are present. This should not be treated as a synonym for an “in operation” test. “At rest” and “in operation” are defined cleanroom occupancy states used for classification and qualification testing, while PQ is a qualification stage.

Step-by-Step Cleanroom Validation Procedure

Here is a simplified version of how the process usually runs from start to finish:

Define the user requirements: Set out the intended use, ISO class target, product being handled, and applicable GMP requirements.
Design review and Design Qualification: Confirm the HVAC, filtration, and layout plans match the required classification and verify that the proposed design meets the URS and GMP requirements. FAT and SAT may also be performed where applicable.
Installation Qualification: Verify equipment and construction match the approved design.
Operational Qualification: Test the systems across defined operating ranges and perform the applicable cleanroom qualification tests, including particle counts, airflow performance, and pressure cascades.
Performance Qualification: Test the qualified systems under intended operating conditions, including with staff, equipment, and applicable simulated or routine operational conditions.
Documentation and sign-off: Compile all test data, deviations, and corrective actions into a validation or qualification report.
Ongoing monitoring and requalification: Set a schedule to retest and confirm the room stays within its qualified conditions and applicable classification requirements over time.

Next steps after this usually involve setting up a routine monitoring plan performance drift can be identified between formal requalification activities.

Common Tests Performed During Validation

A handful of tests show up in nearly every cleanroom qualification project:

Particle count testing: Measures airborne particles against the ISO class limit.
Airflow velocity and volume testing: Checks that the cleanroom receives the required airflow volume and velocity and supports verification of designed air-change performance where applicable.
Differential pressure testing: Confirms the designed pressure cascade is maintained between adjoining areas. FDA guidance gives at least 10–15 Pa between adjacent rooms of differing classification as an example, while EU/PIC/S Annex 1 gives a minimum 10 Pa guidance value between adjacent rooms of different grades. Different pressure relationships may be required where containment is necessary.
HEPA filter integrity testing: Uses a suitable aerosol challenge such as PAO or DOP, followed by downstream scanning, to identify leakage through the filter media, frame, or seals. This is different from HEPA efficiency testing; FDA guidance describes an intact HEPA filter as capable of retaining at least 99.97% of particles greater than 0.3 microns.
Temperature and humidity monitoring: Tracked against product and process requirements.
Recovery testing: Measures how quickly the room returns to its cleanliness class after a disturbance.
Airflow direction and visualization testing: Demonstrates how air moves through the cleanroom and whether airflow patterns provide appropriate protection to critical areas.
Microbial airborne and surface contamination testing: Assesses microbiological contamination as part of qualification where required by the applicable GMP framework.
Containment leak testing: Performed where relevant to the cleanroom design and intended operation.

How Often Should You Requalify?

This is one of the most common questions we hear, and the answer depends on the applicable GMP framework, cleanroom grade, intended use, risk assessment, and facility procedures—not ISO class alone. ISO 14644-2 requires a monitoring plan for cleanroom performance but does not prescribe a universal six-month or annual requalification interval based only on whether a room is ISO Class 5, 6, 7, or 8.

For sterile facilities following EU/PIC/S Annex 1, the maximum time interval for requalification is six months for Grade A and B areas and 12 months for Grade C and D areas. Requalification should also be performed after relevant remedial actions or changes to equipment, facilities, HVAC settings, or processes that may affect the qualified state.

Modular Pharmacy Clean Rooms and Validation

More facilities are turning to modular pharmacy clean rooms accessories because they can reduce on-site construction activities without changing the applicable compliance requirements. A modular build still needs to go through the same applicable qualification lifecycle, including IQ, OQ, and PQ as defined by the qualification strategy, as a conventionally built room. The difference is in how the cleanroom components are fabricated, supplied, and installed. Prefabricated panels, factory-integrated components, and standardized joints can reduce on-site installation variability and support a more efficient qualification process, while all predefined qualification acceptance criteria still need to be met.

Where Pharma Project Management Comes In

A validation procedure does not depend on technical testing alone. Qualification delays can also result from poor coordination between project disciplines. Someone orders the wrong filter grade, a contractor completes work before coordinated services are installed, or test data gets logged in three different formats across three teams.

Good pharma project management keeps design, construction, and validation teams working off the same timeline and the same specifications. It also means a more structured approach to inspection readiness, since documentation gets built as the project moves instead of stitched together afterward.

Cleanroom Qualification and Pharma Consultants in India

India has a large pharmaceutical manufacturing base, and that means facility owners need partners who understand both the ISO standards and the applicable Indian GMP framework. Working with experienced Pharma Consultants in India can help coordinate engineering and qualification activities with revised Schedule M requirements, applicable CDSCO expectations, and the requirements of intended export markets where relevant.

At Pharma Access, we work on engineering design, construction, and CQV (commissioning, qualification, and validation) for pharma facilities across India and beyond. If your project needs pharmaceutical cleanroom, from modular builds to full turnkey execution, our team coordinates the agreed design, construction, and CQV scope to support documented qualification and the facility owner’s GMP and inspection-readiness objectives. You can read more about our approach on the Pharma Access about page.

Wrapping Up

Cleanroom qualification is not a single test. It is a chain of checks, from installation through operational and performance qualification, all measured against defined ISO classification criteria and applicable GMP requirements. Follow the sequence, document the results, and maintain a justified monitoring and requalification programme. That is what supports continued control, compliance, and production readiness.

FAQs

What is the difference between cleanroom classification and cleanroom validation?

Classification is the test that assigns an ISO class based on particle counts. Cleanroom qualification is the broader documented process that assesses whether the cleanroom and its supporting systems are suitable for their intended use through applicable tests and qualification activities. In pharmaceutical GMP terminology, “validation” is more appropriately associated with manufacturing processes, although “cleanroom validation” is commonly used as a broader industry and search term.

How long does the validation process take?

It depends on room size and class, but the time required to complete cleanroom qualification varies according to facility readiness, room count, qualification scope, testing requirements, deviations, corrective actions, retesting, and documentation review. For that reason, there is no single regulatory timeframe that applies to every pharmaceutical cleanroom.

Do modular pharmacy clean rooms need the same validation as traditional builds?

Yes. Modular construction changes how the room is fabricated and installed, not the applicable qualification requirements. Every modular room still goes through the qualification stages defined in the approved project strategy, including IQ, OQ, and PQ where applicable, against its target classification and GMP requirements.

What happens if a cleanroom fails requalification testing?

The team identifies the cause, such as a filter leak or pressure imbalance, corrects it, and retests as required before the cleanroom is returned to routine use. The impact should be assessed and the deviation, investigation, corrective actions, and requalification activities should be documented through the facility’s pharmaceutical quality system.

Who can perform cleanroom validation testing?

Appropriately trained and qualified personnel using calibrated particle counters and airflow instruments typically run the tests. Many facilities bring in specialized consultants or their EPC partner’s CQV team to handle this stage. Where third parties perform qualification activities or provide protocols, appropriate personnel at the manufacturing site remain responsible for confirming their suitability and compliance with the manufacturer’s approved procedures and quality system.

Overview

Engineering Design

Design & Build

Project Management

What Is ALCOA+, and Why Does It Matter So Much?

The Regulatory Backbone: 21 CFR Part 11, EU GMP Annex 11 and GAMP 5

21 CFR Part 11 Requirements for Electronic GxP Records

EU GMP Annex 11 and Computerised Systems

GAMP 5 and Risk-Based Computerised System Validation

Audit Trail Pharmaceutical Systems: The Evidence Behind Every Record

How Automation Helps Pharma Manufacturers Build Data Integrity In

Several of these risks can be reduced by automated systems by design:

MES and QMS in Pharma: Where Data Integrity Lives Day to Day

BMS EMS Pharma: Data Integrity Beyond the Production Floor

Designing for Data Integrity, Not Inspecting for It

Common Data Integrity Failures and How Design Prevents Them

Why This Matters at the Facility Design Stage

Wrapping Up

FAQs

A Quick Recap of Where Things Stand

Why Engineering Gaps Are the Harder Problem

Where Pharmaceutical Plant Layout Design Falls Short

The HVAC Problem Nobody Budgeted For

Brownfield Pharma Upgrades: A Different Kind of Project

What This Means for Plant Owners Right Now

A Few Final Thoughts

Frequently Asked Questions

What GMP Actually Means for a Pharma Plant

For a factory, this means just about everything:

How the GCC Handles Drug Registration and GMP

The basic idea behind GCC central drug registration GMP rules is:

Core GMP Facility Requirements in the GCC

Building and Premises Design

Cleanrooms and HVAC Systems

Equipment and Utilities

Documentation and Quality Systems

Personnel and Training

Saudi Arabia’s SFDA and Its GMP Framework

Steps to Get a Pharmaceutical Factory GCC-Ready

Common Challenges Manufacturers Run Into

Why Early Engineering Input Matters

A Few Final Thoughts

Frequently Asked Questions

Why Cold Chain Warehouse Design Is Different

The Regulatory Backbone: GDP

GDP typically expects a few things from a warehouse:

Main Elements of Pharmaceutical Cold Chain Warehouse Design

Zoning and Layout

HVAC and Refrigeration System Design

Backup Power and Redundancy

Temperature Mapping: Proving the Design Works

A typical mapping study goes as follows:

Common Design Mistakes to Avoid

Designing for Biologics

Bringing It Together at the Design Stage

A Few Final Thoughts

Frequently Asked Questions

Why Cleaning Validation Limits Changed

What Is HBEL Pharmaceutical Guidance Actually Asking For?

From PDE to MACO: How the Numbers Actually Work

Often the calculation is done with a version like this:

HPAPI Cleaning Validation: Where the Stakes Get Higher

Cleaning Method Selection Follows the Numbers

Brownfield Pharma Upgrades and Cleaning Validation

Building Cleaning Validation Into Facility Design From the Start

Wrapping Up

FAQs

What Do IQ, OQ, and PQ Actually Mean?

DQ: The Step Before IQ

DQ IQ OQ PQ Equipment Qualification in Pharma: The Full Sequence

Installation Qualification (IQ) is the first step. It confirms that:

Operational Qualification (OQ): OQ tests the actual functions of the equipment. In this stage, it checks things like:

Performance Qualification (PQ)

IQ OQ PQ Examples: What This Looks Like in Practice

Facility Qualification vs Equipment Qualification

Why IQ, OQ, and PQ in the Pharmaceutical Industry Matter So Much

Common Mistakes Facilities Make With IQ, OQ, and PQ

Where This Fits Into the Bigger Picture: Commissioning Qualification Validation

How This Connects to Facility Design and Construction

Getting IQ, OQ, and PQ Right the First Time